Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Myopia control
Author Affiliations & Notes
  • Takahiro Hiraoka
    University of Tsukuba, Tsukuba, IBARAKI, Japan
  • Footnotes
    Commercial Relationships   Takahiro Hiraoka None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4911. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takahiro Hiraoka; Myopia control. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4911.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : The prevalence of myopia is high in East Asian countries such as China, Japan, and Singapore and has been reported to be increasing globally. A range of optical interventions have been developed to slow the progression of myopia, and many sophisticated studies have been conducted in the last two decades. This presentation will summarize key studies and their outcomes on myopia control using contact lenses (CLs) such as orthokeratology and multifocal soft CLs.

Orthokeratology trials have consistently shown a 2-year slowing of axial elongation between 0.24 and 0.32 mm. Among soft CL interventions, a dual-focus concentric design resulted in a 3-year axial elongation and myopia progression reduction of 0.32 mm and 0.73 D. Extended depth of focus designs reduced these values by 0.41 to 0.46 mm and 0.78 to 0.84 D, respectively. More recently, very promising myopia control effects of a novel soft CL with a noncoaxial ring-focus design have been reported, although it was a short-term observation. All of the above optical interventions have the potential to significantly slow myopia progression. Quality of vision is largely unaffected, and safety is satisfactory. Areas of uncertainty include the potential for post-treatment acceleration of progression (rebound phenomena). The potential benefit of adding low-concentration atropine eye drops to optical interventions will also be discussed.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×